{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0000", "char_start": 0, "char_end": 2000, "pages": [1], "text": "July 2022\nVolume 38 | Number 8\nMedicaid Pharmacy Prior Authorization Programs Update\nOn May 12, 2022, the New York State (NYS) Medicaid Drug Utilization Review (DUR) Board recommended\nchanges to the NYS Medicaid pharmacy prior authorization (PA) programs. The Commissioner of Health has\nreviewed the DUR Board recommendations and has approved changes to the Preferred Drug Program (PDP)\nwithin the fee-for-service (FFS) pharmacy program.\nEffective August 11, 2022, PA requirements will change for some drugs in the following PDP classes:\n• Cholesterol Absorption Inhibitors\n• Antimigraine Agents, Other\n• Movement Disorder Agents\n• Antifungals, Topical\n• Dipeptidyl Peptidase-4 (DPP-4) Inhibitors\n• Glucagon-like Peptide-1 (GLP-1) Agonists\n• Antihyperuricemics\n• Anticholinergic/COPD Agents\nEffective August 11, 2022, criteria for the following drugs will include:\nSpravato® (esketamine) nasal spray\n• PA will be required when Spravato® (esketamine) is prescribed to confirm the following requirements\nhave been met:\nBefore initiating Spravato® (esketamine), prescribers must attest that they have obtained a\nbaseline score using a validated clinical assessment tool for depression [e.g., Hamilton\nDepression Rating Scale (HAMD-17), Quick Inventory of Depressive Symptomatology (QIDS-\nC16C), Montgomery-Asberg Depression Rating Scale (MADRS)].\nTrial of at least two oral antidepressants prior to Spravato® (esketamine) when used for\nTreatment Resistant Depression.\nAfter the initiation of Spravato® (esketamine) therapy, every six months prescribers must attest\nthat Spravato® (esketamine) has resulted in an improvement of depressive symptoms, from\nbaseline, using the same baseline clinical assessment tool for depression (e.g., HAMD-17,\nQIDS-C16C, MADRS).\nSymbicort® (budesonide/formoterol) and Dulera® (mometasone/formoterol)\n• The quantity limit (QL) for Dulera® (mometasone/formoterol) and Symbicort® (budesonide/formoterol)\nwill allow for the dispensing of up to two additional inhalers over a", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0001", "char_start": 1750, "char_end": 3750, "pages": [1, 2], "text": " MADRS).\nSymbicort® (budesonide/formoterol) and Dulera® (mometasone/formoterol)\n• The quantity limit (QL) for Dulera® (mometasone/formoterol) and Symbicort® (budesonide/formoterol)\nwill allow for the dispensing of up to two additional inhalers over a 180-day period.\nContinued on Page 3\n***************************************************************************************************************\n\nKathy Hochul\nGovernor\nState of New York\nMary T. Bassett, M.D., M.P.H.\nCommissioner\nNew York State\nDepartment of Health\nAmir Bassiri\nMedicaid Director\nOffice of Health Insurance Programs\nThe Medicaid Update is a monthly publication of the New York State Department of Health.\nIn This Issue…\nMedicaid Pharmacy Prior Authorization Programs Update ........................................................................................ Cover\nPolicy and Billing\nClarification of Previous Guidance:\nNew York State Medicaid Fee-for-Service Coverage of Practitioner Administered Drugs ................................................ 4\nPolicy Clarification for Practitioner Dispensing ................................................................................................................... 8\nNew Attestation Form for New York State Medicaid Members Enrolled in Qualifying Clinical Trials ................................ 9\nUpdated Fees for Physicians, Nurse Practitioners, and Midwives ................................................................................... 10\nUpdated Billing Guidance for Postpartum Maternal Depression Screening .................................................................... 11\nAll Providers\nUpdated Identification, Specimen Collection, Testing, Vaccine Administration,\nand Treatment for Suspected Cases of Orthopoxvirus/Monkeypox................................................................................. 13\nNew York State Department of Health Launches Health Care Worker Bonus Program ................................................. 17\nMedicaid Cons", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0002", "char_start": 3500, "char_end": 5500, "pages": [2, 3], "text": "thopoxvirus/Monkeypox................................................................................. 13\nNew York State Department of Health Launches Health Care Worker Bonus Program ................................................. 17\nMedicaid Consumer Fact Sheets Now Available ............................................................................................................. 18\nProvider Directory ............................................................................................................................................................. 19\nJuly 2022 New York State Medicaid Update pg. 2\n\nPharmacy\nQuestions and Additional Information:\n• Detailed information on the DUR Board can be found on the NYS Department of Health (DOH) “Drug\nUtilization Review (DUR)” web page, located at: http://www.health.ny.gov/health_care/medicaid/\nprogram/dur/index.htm.\n• A full listing of drugs subject to the NYS Medicaid FFS pharmacy programs and up-to-date information\non the NYS Medicaid FFS pharmacy PA programs can be found on the New York State Medicaid Fee-\nFor-Service Pharmacy Programs document, located at: https://newyork.fhsc.com/downloads/\nproviders/NYRx_PDP_PDL.pdf.\n• To obtain a PA, providers should contact the clinical call center at (877) 309-9493. The clinical call\ncenter is available 24 hours a day and seven days per week with pharmacy technicians and\npharmacists who will work with you, or your agent, to quickly obtain a PA.\n• NYS Medicaid-enrolled prescribers can also initiate PA requests using the web-based application,\nPAXpress®. PAXpress® is a web-based pharmacy PA request/response application accessible\nthrough eMedNY (providers can refer to the “PAXpress” button located on the right-hand side of the\neMedNY homepage, at: https://www.emedny.org/index.aspx), or the PAXpress® website, located at:\nhttps://paxpress.nypa.hidinc.com/apex/f?p=109:1.\n• Additional information is available at the following websites:\nNYS DOH (https://www.health.ny.gov)\nMag", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0003", "char_start": 5250, "char_end": 7250, "pages": [3, 4], "text": "e\neMedNY homepage, at: https://www.emedny.org/index.aspx), or the PAXpress® website, located at:\nhttps://paxpress.nypa.hidinc.com/apex/f?p=109:1.\n• Additional information is available at the following websites:\nNYS DOH (https://www.health.ny.gov)\nMagellan Health, Inc. Medicaid Administration (https://newyork.fhsc.com/)\neMedNY (https://www.emedny.org/index.aspx)\n• For practitioner administration, the Spravato® Clinical Criteria Worksheet is located on the NYS DOH\nNew York State Medicaid Fee-for-Service Practitioner Administered Drug Policies and Billing\nGuidance web page, at: https://www.health.ny.gov/health_care/medicaid/program/practitioner\n_administered/ffs_practitioner_administer.htm.\n***************************************************************************************************************\nJuly 2022 New York State Medicaid Update pg. 3\n\nPolicy and Billing\nClarification of Previous Guidance: New York State Medicaid\nFee-for-Service Coverage of Practitioner Administered Drugs\nNew York State (NYS) Medicaid fee-for-service (FFS) has specific policies and billing guidance in place for\nPractitioner Administered Drugs (PADs) — outpatient drugs administered by providers in a medical office or\noutpatient clinic setting. This article provides clarification on, and consolidation of, existing guidance.\nA list of covered PADs is available on the eMedNY “Physician Manual” web page, located at:\nhttps://www.emedny.org/ProviderManuals/Physician/index.aspx, within the following manuals:\n• Procedure Codes: Medicine and Drugs, located directly at: https://www. emedny.org\n/ProviderManuals/Physician/PDFS/Physician_Procedure_Codes_Sect2.pdf.\n• Ordered Ambulatory Procedure Codes, located directly at: https://www.emedny.org/\nProviderManuals/OrderedAmbulatory/PDFS/OrderedAmbulatory_Procedure_Codes.pdf.\n• Nurse Practitioner Fee Schedule, located directly at: https://view.officeapps.live.com/op\n/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2FNursePractitioner%2\nFPDFS%2FN", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0004", "char_start": 7000, "char_end": 9000, "pages": [4], "text": "ls/OrderedAmbulatory/PDFS/OrderedAmbulatory_Procedure_Codes.pdf.\n• Nurse Practitioner Fee Schedule, located directly at: https://view.officeapps.live.com/op\n/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2FNursePractitioner%2\nFPDFS%2FNurse_Practitioner_Fee_Schedule.xls&wdOrigin=BROWSELINK\nA list of covered PADs is also available within the Policy and Billing Guidance Ambulatory Patient Groups\n(APGs) Provider Manual, located at: https://www.health.ny.gov/health_care/medicaid/rates/apg/docs/\napg_provider_manual.pdf.\nNYS Medicaid FFS policy for drugs administered by subcutaneous, intramuscular, or intravenous methods in\nthe practitioner’s office are covered for Food and Drug Administration (FDA) approved indications, or where\nthe medically accepted indication is supported in any of the compendia described in Social Security Act\n§1927(g)(1)(B)(i) for a medically necessary NYS Medicaid-covered service. In the absence of such a\nrecognized indication, an approved Institutional Review Board (IRB) protocol would be required with\ndocumentation maintained in the patient's clinical file. Drugs are not covered for investigational or\nexperimental use.\nThe NYS Medicaid program has also issued policies and billing guidance for certain drugs/drug classes.\nThese drugs are eligible for reimbursement when the clinical criteria outlined on the NYS Department of\nHealth (DOH) New York State Medicaid Fee-for-Service Practitioner Administered Drug Policies and Billing\nGuidance web page, located at https://www.health.ny.gov/health_care/medicaid/program/practitioner_\nadministered/ffs_practitioner_administer.htm, and listed web page Medicaid Update articles, are met. Drug\nclaims must include documentation of clinical criteria as well as the following:\n• manufacturer invoice showing the actual acquisition cost of the biologic, including all discounts,\nrebates, or incentives;\nthe invoice, which must be dated within six months prior to the date of service and/or should\ninclude the ", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0005", "char_start": 8750, "char_end": 10750, "pages": [4, 5], "text": " as the following:\n• manufacturer invoice showing the actual acquisition cost of the biologic, including all discounts,\nrebates, or incentives;\nthe invoice, which must be dated within six months prior to the date of service and/or should\ninclude the expiration date of the drug;\n• documentation of the medication administration; and\n• documentation of the criteria listed under the \"NYS Medicaid Coverage Policy\" sections of the\ndrug-specific policies (issued in the Medicaid Update articles on the NYS DOH \"New York State\nMedicaid Fee-for-Service Practitioner Administered Drug Policies and Billing Guidance\" web page,\nlocated at: https://www.health.ny.gov/health_care/medicaid/program/practitioner_administered\n/ffs_practitioner_administer.htm).\nClinical Criteria Worksheets are available for some drugs/drug classes subject to clinical criteria. These\nworksheets are designed to ensure claim documentation and outline completion as well as provide step-by-\nstep clinical and claim documentation requirements for drugs. Legible, completed worksheets can be\nsubmitted in lieu of detailed medical documentation.\nJuly 2022 New York State Medicaid Update pg. 4\n\nCodes Listed “By Report”\nThere are certain drugs on the Physician Manual Fee Schedule, located at: https://view.\nofficeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2FPhysic\nian%2FPDFS%2FPhysician_Manual_Fee_Schedule_Sect3.xls&wdOrigin=BROWSELINK, and on the\nOrdered Ambulatory Fee Schedule, located at: https://view.officeapps.live.com/op/view.aspx?\nsrc=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2FOrderedAmbulatory%2FPDFS%2FOrder\nedAmbulatory_Fee_Schedule.xls&wdOrigin=BROWSELINK, that are designated “By Report” (“BR”). For\nthose PADs that are newly FDA-approved or have no assigned Healthcare Common Procedure Coding\nSystem (HCPCS) code, the use of an unclassified code may be required when submitting a claim BR. An\nitemized invoice representing the actual acquisition cost is required with claim s", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0006", "char_start": 10500, "char_end": 12500, "pages": [5], "text": "FDA-approved or have no assigned Healthcare Common Procedure Coding\nSystem (HCPCS) code, the use of an unclassified code may be required when submitting a claim BR. An\nitemized invoice representing the actual acquisition cost is required with claim submission, inclusive of all\ndiscounts and rebates.\nWhen the value of a procedure is to be determined BR, information concerning the nature, extent and need\nfor the procedure or service, time, skill, and the equipment necessary, is to be furnished. Appropriate\ndocumentation (e.g., operative report, procedure description, and/or itemized invoices) should accompany all\nclaims submitted, as this will determine medical appropriateness. Itemized invoices must document the\nacquisition cost, line-item cost from a manufacturer or wholesaler net of any rebates, or other valuable\nconsiderations. Additional information is available on the Ordered Ambulatory Fee Schedule, located at:\nhttps://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManual\ns%2FOrderedAmbulatory%2FPDFS%2FOrderedAmbulatory_Fee_Schedule.xls&wdOrigin=BROWSELINK,\nand on the Fee Schedule Column Descriptions, located at: https://www.emedny.org/ProviderManuals\n/AllProviders/PDFS/Fee_Schedule_Column_Descriptions.pdf.\nNational Drug Code Reporting Requirements\nProviders are required to report the National Drug Code (NDC) for all PADs billed by a private practitioner to\nNYS Medicaid and for all ordered ambulatory claims billed by clinics. If the NDC is not referenced on a claim,\nNYS Medicaid will not provide reimbursement for the drug.\nDrugs obtained via the 340B program must be identified by appending the UD modifier to the 340B drug line\non submitted NYS Medicaid FFS-only claims. Providers are required to report the NDC on FFS claims for the\nreimbursement of 340B drugs. Providers must also include the number of units administered and their actual\nacquisition cost, by invoice, in the charges field of a claim. Please note: Medicare requires", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0007", "char_start": 12250, "char_end": 14250, "pages": [5], "text": " required to report the NDC on FFS claims for the\nreimbursement of 340B drugs. Providers must also include the number of units administered and their actual\nacquisition cost, by invoice, in the charges field of a claim. Please note: Medicare requires either the JG or\nTB modifiers be appended to the 340B drug line for Medicare/NYS Medicaid crossover claims (no UD modifier\nis needed on crossover claims).\nAn accurate NDC must be reported for all PADs billed to NYS Medicaid FFS on an institutional claim that\nuses Ambulatory Patient Groups (APGs) payment methodology. Additional guidance is available in the\nReporting of the National Drug Code is Required for all Fee-for-Service Physician Administered Drugs article,\npublished in the April 2019 issue of the Medicaid Update, located at: https://www.health.ny.gov/health_care\n/medicaid/program/update/2019/apr19_mu.pdf.\nUse of JW Modifier\nNYS Medicaid FFS will reimburse providers for the unused, appropriately discarded, portion of a drug or\nbiologic from a single-use vial/package when providers use the JW modifier. Drug waste from multi-use\nvials/packages will not be reimbursed. Providers must clearly report on a claim the portion of the drug\nadministered and the portion wasted for a claim to be billable. Payment will not exceed the maximum amount\nof the drug/biologic as indicated on the single-use vial/package's label. Information should be reported on two\nlines as follows:\n• Line One: The HCPCS drug code and number of units administered. Providers administering a\nportion of a unit should round up to the nearest unit. If, through rounding up, the number of units\nreported on line one equals the total number of units contained in the single-use vial/package, then\nthe JW modifier should not be reported.\n• Line Two: The HCPCS drug code, appended with the JW modifier and number of units not\nadministered/discarded. Units discarded reported on line one (through rounding up to the nearest\nunit) should not be reported again on line two", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0008", "char_start": 14000, "char_end": 16000, "pages": [5, 6], "text": "ld not be reported.\n• Line Two: The HCPCS drug code, appended with the JW modifier and number of units not\nadministered/discarded. Units discarded reported on line one (through rounding up to the nearest\nunit) should not be reported again on line two.\nJuly 2022 New York State Medicaid Update pg. 5\n\nAdditional information on the use of the JW modifier can be found in the Clarification of Policy for Practitioner,\nOrdered Ambulatory, and APG Reimbursement and New Billing Instructions for Wasted Drugs Using JW\nModifier article, published in the August 2015 issue of the Medicaid Update, located at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2015/august15_mu.pdf.\nPaper claim submission and multiple drug procedure codes, including wastage, must be submitted for the\nsame date of service on separate claim forms. Additional information on paper claim submission can be found\nin the Billing Instructions for Physician-Administered Drugs (J-codes) Submitted on Paper Claims article,\npublished in the December 2008 issue of the Medicaid Update, located at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2008/2008-12.htm#ins.\nPractitioner Billing\nReimbursement for drugs, including vaccines and immune globulins, furnished by practitioners to their\npatients, is based on the acquisition cost to the practitioner. For all items furnished in this fashion, practitioners\nare expected to maintain auditable records of the actual itemized invoice cost of the drug. This includes the\nnumbers of doses of the drug represented on the invoice. NYS Medicaid FFS does not intend to pay more\nthan the actual acquisition cost of the drug dosage, as established by invoice, to the practitioner. Regardless\nof whether an invoice must be submitted to NYS Medicaid for payment, practitioners must limit the NYS\nMedicaid claim amount to the actual invoice cost of the item administered. The maximum fees for these drugs\nare adjusted periodically by the State to reflect the estimated a", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0009", "char_start": 15750, "char_end": 17750, "pages": [6], "text": "t be submitted to NYS Medicaid for payment, practitioners must limit the NYS\nMedicaid claim amount to the actual invoice cost of the item administered. The maximum fees for these drugs\nare adjusted periodically by the State to reflect the estimated acquisition cost. An itemized invoice\nrepresenting the actual acquisition cost is required with claim submission, inclusive of all discounts and\nrebates.\nVaccines and the Vaccines for Children (VFC) Program\nNYS Medicaid FFS covers medically necessary vaccines as recommended by the Centers for Disease\nControl and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Additional information\non ACIP vaccine recommendations and guidelines can be found on the CDC “ACIP Vaccine\nRecommendations and Guidelines” web page, located at: https://www.cdc.gov/vaccines/hcp/acip-\nrecs/index.html. Additional policy and billing guidance on vaccines, including VFC vaccines, can be found in\nthe Medicaid Fee-for Service Coverage Policy and Billing Guidance for Vaccinations article, published in the\nJuly 2020 issue of the Medicaid Update, located at: https://www.health.ny.gov/health\n_care/medicaid/program/update/2020/docs/mu_no12_jul20.pdf. Additional information on the VFC program\nis available on the NYS DOH “New York State Vaccines for Children (VFC) Program” web page, located at:\nhttps://www.health.ny.gov/prevention/immunization/vaccines_for_children.htm\nOutpatient Clinic Billing\n340B Covered Entities and Claim Level Identifiers\nAll NYS Medicaid FFS-only claims for 340B drugs must be submitted at actual acquisition cost (per invoice),\ninclusive of all discounts and appended with the UD modifier. Please note: Medicare requires either the\nJG or TB modifiers be appended to the 340B drug line for Medicare/NYS Medicaid crossover claims (no UD\nmodifier is needed on crossover claims). Additional information on FFS claims for 340B drugs can be found\nin the Reminder: NYS Medicaid Requirements for 340B Claim Identification article, publ", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0010", "char_start": 17500, "char_end": 19500, "pages": [6, 7], "text": "ug line for Medicare/NYS Medicaid crossover claims (no UD\nmodifier is needed on crossover claims). Additional information on FFS claims for 340B drugs can be found\nin the Reminder: NYS Medicaid Requirements for 340B Claim Identification article, published in the June\n2017 issue of the Medicaid Update, located at: https://www.health.ny.gov/health_care/medicaid/\nprogram/update/2017/jun17_mu.pdf. For ease of reference, regarding the use of modifier codes for APGs,\nuse the following table located on the NYS DOH “NYS APG Modifiers” web page, located at:\nhttps://www.health.ny.gov/health_care/medicaid/rates/methodology/modifiers.htm.\nBilling APG Group Drugs\nProviders should not bill multiple claim lines with the same J-code drugs on the same date of service, even if\nthe drugs administered have different NDCs. Providers should combine all units of the J-code drug\nadministered and bill it on one claim line reporting the NDC that has the highest number of units administered.\nIf the same number of units were administered for each NDC/J-code, providers should choose one NDC to\nuse for the submitted claim.\nJuly 2022 New York State Medicaid Update pg. 6\n\nBilling APG Fee Schedule Drugs\nProviders may continue to code multiple lines to denote different NDCs only when billing for PADs through\nthe APG Fee Schedule, located on the NYS DOH “APG and Px-Based Weights History and APG Fee\nSchedules” web page, at: https://www.health.ny.gov/health_care/medicaid/rates/methodology/history_\nand_fee_schedule.htm. Physician services carved out of APG or All Patients Refined Diagnosis Related\nGroups (APR-DRG) payments for services provided in ambulatory surgery settings, emergency departments\n(EDs), inpatient settings, and Article 28 hospital outpatient clinics can be found in the Changes to Medicaid\nfee-for-service reimbursement policy for practitioner services provided in hospital settings article, published\nin the March 2010 issue of the Medicaid Update, located at: https://www.health.ny.gov/hea", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0011", "char_start": 19250, "char_end": 21250, "pages": [7], "text": " clinics can be found in the Changes to Medicaid\nfee-for-service reimbursement policy for practitioner services provided in hospital settings article, published\nin the March 2010 issue of the Medicaid Update, located at: https://www.health.ny.gov/health_care/\nmedicaid/program/update/2010/2010-03.htm.\nAdditional information on APGs can be found in the Ambulatory Patient Groups (APGs) Medicaid Fee-for-\nService Provider Manual Policy and Billing Guidelines, located at:\nhttps://www.health.ny.gov/health_care/medicaid/rates/manual/docs/apg_provider_manual_december.pdf.\nAdditional information regarding implementation, weights, and additional web resources pertaining to the APR\ngrouper can be found on the NYS DOH “All Patient Refined Diagnosis Related Groups (APR-DRGs)” web\npage, located at: https://www.health.ny.gov/facilities/hospital/reimbursement/apr-drg/. The “Never Pay” APGs\nand procedures lists are available on the NYS DOH “Never Pay Lists” web page, located at:\nhttps://www.health.ny.gov/health_care/medicaid/rates/methodology/apg_carve_out.htm.\nFree-Standing Diagnostic and Treatment Centers or Hospital-Based Ordered Ambulatory\nClinics\nCertain drugs [e.g., Chemotherapy (APG 430-434, 441, and 443), Class XIII and XIV Combined\nChemotherapy and Pharmacotherapy Drugs (APG 465 and 466), Minor Chemotherapy Drugs (APG 495),\nand Class IV Therapeutic Radiopharmaceuticals (APG 246)] are carved out of the APG reimbursement\nmethodology. Providers should seek reimbursement for these services via the eMedNY Ordered Ambulatory\nFee Schedule, located at: https://www.emedny.org/ProviderManuals/OrderedAmbulatory/. The “Never Pay”\nAPGs and procedures lists are available on the NYS DOH “Never Pay Lists” web page, located at:\nhttps://www.health.ny.gov/health_care/medicaid/rates/methodology/apg_carve_out.htm.\nAdditional information on the reimbursement for carved-out drugs and therapies, such as chimeric antigen\nreceptor (CAR) T-cell therapies, can be found in the New York State Medicaid Fe", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0012", "char_start": 21000, "char_end": 23000, "pages": [7, 8], "text": ".ny.gov/health_care/medicaid/rates/methodology/apg_carve_out.htm.\nAdditional information on the reimbursement for carved-out drugs and therapies, such as chimeric antigen\nreceptor (CAR) T-cell therapies, can be found in the New York State Medicaid Fee-for-Service Policy and\nBilling Guidance for Chimeric Antigen Receptor T-cell Therapy article, published in the October 2021 issue of\nthe Medicaid Update, located at: https://www.health.ny.gov/health_care/medicaid/program/update\n/2021/no12_2021-10.htm. Codes listed as “BR” on the Ordered Ambulatory Fee Schedule should be\nsubmitted as an ordered ambulatory claim on paper (using eMedNY 150003 claim form) and should include\nthe hospital actual acquisition cost by invoice. Additionally, the following documentation must be included with\nthe claim:\n• manufacturer’s invoice showing the acquisition cost of the drug/biologic, including all discounts,\nrebates, and incentives;\n• documentation of the medication administration; and\n• documentation of medical necessity, such as FDA-approved indications and/or Compendia-supported\nuse, must accompany the claim. Ordered ambulatory billing guidelines can be found in the eMedNY\nNYS 150003 Billing Guidelines - Free Standing or Hospital Based Ordered Ambulatory, located at:\nhttps://www.emedny.org/ProviderManuals/OrderedAmbulatory/PDFS/OrderedAmbulatory_Billing_G\nuidelines.pdf.\nJuly 2022 New York State Medicaid Update pg. 7\n\nQuestions and Additional Information:\n• Medicaid FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000.\n• Medicaid FFS coverage and policy questions should be directed to the Office of Health Insurance\nPrograms (OHIP) Division of Program Development and Management (DPDM) by telephone at\n(518) 473-2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• Medicaid FFS Pharmacy coverage and policy questions should be directed to the Medicaid Pharmacy\nPolicy Unit by telephone at (518) 486-3209 or by email at PPNO@health.ny.gov.\n• Medicaid Managed Ca", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0013", "char_start": 22750, "char_end": 24750, "pages": [8], "text": "2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• Medicaid FFS Pharmacy coverage and policy questions should be directed to the Medicaid Pharmacy\nPolicy Unit by telephone at (518) 486-3209 or by email at PPNO@health.ny.gov.\n• Medicaid Managed Care (MMC) general coverage questions should be directed to the OHIP Division\nof Health Plan Contracting and Oversight (DHPCO) by email at covques@health.ny.gov or by\ntelephone at (518) 473-1134.\n• MMC reimbursement, billing, and/or documentation requirement questions should be directed to the\nenrollee’s MMC Plans.\n• MMC Plan contact information can be found in the eMedNY New York State Medicaid Program\nInformation for All Providers – Managed Care Information document, located at:\nhttps://www.emedny.org/ProviderManuals/AllProviders/PDFS/Information_for_All_Providers_Manag\ned_Care_Information.pdf.\n• MMC plan-specific policies and billing guidance for PADs can be found on the NYS DOH “New York\nState Medicaid Managed Care (MMC) Pharmacy Benefit Information Center” website, located at:\nhttps://mmcdruginformation.nysdoh.suny.edu.\n***************************************************************************************************************\nPolicy Clarification for Practitioner Dispensing\nThe following guidance supersedes previous communications on this topic. New York State Education\n(NYSED) Law, Article 137 §6807, authorizes practitioners, who are authorized to prescribe, to dispense\nmedications directly to their patients. Additional registration or ownership of a pharmacy is not required. This\ndispensing must be done in accordance with federal, State, and New York State (NYS) Medicaid program\npolicies for dispensing, billing, and record keeping.\nThe NYS Medicaid program reimburses for drugs furnished by practitioners to their patients on the basis of\nthe acquisition cost to the practitioner of the drug dose provided to the patient. For all drugs dispensed to the\npatient, regardless of whether an invoice must be submitted to N", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0014", "char_start": 24500, "char_end": 26500, "pages": [8, 9], "text": " for drugs furnished by practitioners to their patients on the basis of\nthe acquisition cost to the practitioner of the drug dose provided to the patient. For all drugs dispensed to the\npatient, regardless of whether an invoice must be submitted to NYS Medicaid for payment, the practitioner\nmust, and is expected to, maintain auditable records of, and limit his/her claim amount to, the actual itemized\ninvoice cost of the drug dispensed. Practitioners may not submit an office visit claim for the sole purpose of\ndispensing a drug that the member can obtain at a NYS Medicaid enrolled pharmacy.\nFFS Billing\nNYS Medicaid enrolled practitioners are eligible to bill medications dispensed to a patient via the medical\nclaim format. Practitioners submit using an appropriate Healthcare Common Procedure Coding System\n(HCPCS) code and corresponding National Drug Code (NDC) when billing for a medication for which they\nhave dispensed. If a specific HCPCS code has not been assigned for an oral medication, the following codes\nmay be utilized:\n• “J8999” – Rx Drug Oral Chemotherapy\n• “J8499” – Rx Drug Oral Non-Chemotherapy\nPlease note: The use of the codes provided above will require invoice and policy criteria verification. Policy\nand billing guidelines can be found on the eMedNY “Physician Manual” web page, located at:\nhttps://www.emedny.org/ProviderManuals/Physician/index.aspx.\nJuly 2022 New York State Medicaid Update pg. 8\n\nMMC Billing\nA practitioner participating in Medicaid Managed Care (MMC) should check with the patient’s health plan to\ndetermine the plan billing policy for prescription drugs dispensed directly to a patient. Reminder: A\npractitioner that dispenses prescriptions directly to their patient is not considered a pharmacy and,\ntherefore, are not required to be enrolled as a pharmacy provider.\nQuestions and Additional Information:\n• Medicaid fee-for-service (FFS) claim questions should be directed to the eMedNY Call Center at\n(800) 343-9000.\n• Medicaid FFS coverage and ", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0015", "char_start": 26250, "char_end": 28250, "pages": [9], "text": "nd,\ntherefore, are not required to be enrolled as a pharmacy provider.\nQuestions and Additional Information:\n• Medicaid fee-for-service (FFS) claim questions should be directed to the eMedNY Call Center at\n(800) 343-9000.\n• Medicaid FFS coverage and policy questions should be directed to the Office of Health Insurance\nPrograms (OHIP) Division of Program Development and Management (DPDM) by telephone at\n(518) 473-2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• Medicaid FFS Pharmacy coverage and policy questions should be directed to the Medicaid Pharmacy\nPolicy Unit by telephone at (518) 486-3209 or by email at PPNO@health.ny.gov.\n• MMC general coverage questions should be directed to the OHIP Division of Health Plan Contracting\nand Oversight (DHPCO) by email at covques@health.ny.gov or by telephone at (518) 473-1134.\n• MMC reimbursement, billing, and/or documentation requirement questions should be directed to\nenrollee MMC Plans.\n• MMC Plan contact information can be found in the eMedNY New York State Medicaid Program\nInformation for All Providers Managed Care Information document, located at:\nhttps://www.emedny.org/ProviderManuals/AllProviders/PDFS/Information_for_All_Providers_Manag\ned_Care_Information.pdf.\n• MMC Plan-specific policies and billing guidance for PADs can be found on the NYS DOH “New York\nState Medicaid Managed Care (MMC) Pharmacy Benefit Information Center” website, located at:\nhttps://mmcdruginformation.nysdoh.suny.edu.\n***************************************************************************************************************\nNew Attestation Form for New York State Medicaid Members\nEnrolled in Qualifying Clinical Trials\nIn December 2021, the Centers for Medicare and Medicaid Services (CMS) issued the UPDATED: Mandatory\nMedicaid Coverage of Routine Patient Costs Furnished in Connection with Participation in Qualifying Clinical\nTrials guidance, located at: https://www.medicaid.gov/federal-policy-guidance/downloads/smd21005.pdf,\nrequiring s", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0016", "char_start": 28000, "char_end": 30000, "pages": [9, 10], "text": "sued the UPDATED: Mandatory\nMedicaid Coverage of Routine Patient Costs Furnished in Connection with Participation in Qualifying Clinical\nTrials guidance, located at: https://www.medicaid.gov/federal-policy-guidance/downloads/smd21005.pdf,\nrequiring state Medicaid program coverage of routine costs associated with qualifying clinical trials in which\nmembers are enrolled. The NYS Medicaid program has covered and will continue to cover these costs, and\nis updating policy in compliance with CMS requirements. “Qualifying Clinical Trial” is defined in the referenced\nguidance above. “Routine costs” do not include any investigational item or service that is the subject of the\nqualifying clinical trial and is not otherwise covered outside of the clinical trial under the state plan, waiver, or\ndemonstration project.\nTo comply with CMS’ directive, effective immediately, the Medicaid Attestation Form on the Appropriateness\nof Qualified Clinical Trial, located at: https://www.medicaid.gov/resources-for-states/downloads/medicaid-\nattest-form.docx, must be submitted for each Medicaid member enrolled in a qualifying clinical trial for whom\nMedicaid reimbursement is requested, prior to providing treatment in the trial. For each trial participant who\nis enrolled in either NYS Medicaid fee-for-service (FFS) or Medicaid Managed Care (MMC), the form must be\ncompleted, in full, and must be:\n• signed by the clinical trial’s Principal Investigator (PI),\n• signed by the member’s Health Care Provider, and\n• submitted via the Secure File Transfer Application in the Health Commerce System to Medicaid\nClinical Trial.\nJuly 2022 New York State Medicaid Update pg. 9\n\nOnce a completed form is received, the NYS Department of Health (DOH) will review the attestation and\nmake a coverage determination within 72 hours of its electronic submission. Notification of the coverage\ndetermination will be sent electronically to the submitter within 72 hours.\nQuestions\nAll questions should be sent to MedicaidClin", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0017", "char_start": 29750, "char_end": 31750, "pages": [10], "text": "ttestation and\nmake a coverage determination within 72 hours of its electronic submission. Notification of the coverage\ndetermination will be sent electronically to the submitter within 72 hours.\nQuestions\nAll questions should be sent to MedicaidClinTrials@health.ny.gov.\n***************************************************************************************************************\nUpdated Fees for Physicians, Nurse Practitioners, and Midwives\nAs part of the New York State (NYS) Enacted Budget for fiscal year (FY) 2022-2023, the NYS Department of\nHealth (DOH) was authorized to benchmark non-facility fees for Evaluation and Management (E&M) and\nMedicine codes on the NYS Medicaid Physician Drug and Drug Administration Services Fee Schedule,\nlocated at: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2F\nProviderManuals%2FPhysician%2FPDFS%2FPhysician_Manual_Fee_Schedule_Sect3.xls&wdOrigin=BRO\nWSELINK, to 70 percent of current Medicare rates. Nurse Practitioner (NP) and Midwife (MW) fee schedules\nare benchmarked to the NYS Medicaid Physician Drug and Drug Administration Services Fee Schedule and\nwill receive commensurate increases. Additionally, the benchmark rate for the Midwife (MW) Fee Schedule,\nlocated at: https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2F\nProviderManuals%2FMidwife%2FPDFS%2FMidwife_Fee_Schedule.xls&wdOrigin=BROWSELINK, will\nincrease from 85 percent to 95 percent of the Physician Fee Schedule. This investment in the physician and\nprimary care workforce is expected to improve access to primary and preventative care for NYS Medicaid\nmembers. Effective July 1, 2022, fees for over 500 procedure codes on the NYS Medicaid Physician Drug\nand Drug Administration Services Fee Schedule have increased.\nThe following impacted fee schedules include:\n• NYS Medicaid Physician Medicine Services Fee Schedule (https://view.officeapps.live.com/op/view\n.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2F", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0018", "char_start": 31500, "char_end": 33500, "pages": [10, 11], "text": "stration Services Fee Schedule have increased.\nThe following impacted fee schedules include:\n• NYS Medicaid Physician Medicine Services Fee Schedule (https://view.officeapps.live.com/op/view\n.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2FPhysician%2FPDFS%2FP\nhysician_Manual_Fee_Schedule_Sect2.xls&wdOrigin=BROWSELINK)\n• NYS Medicaid Physician Drug and Drug Administration Services Fee Schedule (https:// view.\nofficeapps.live.com/op/view.aspx?src=https%3A%2F%2Fwww.emedny.org%2FProviderManuals%2\nFPhysician%2FPDFS%2FPhysician_Manual_Fee_Schedule_Sect3.xls&wdOrigin=BROWSELINK)\n• Nurse Practitioner Services Fee Schedule (https://view.officeapps.live.com/op/view.aspx?src=https%\n3A%2F%2Fwww.emedny.org%2FProviderManuals%2FNursePractitioner%2FPDFS%2FNurse_Prac\ntitioner_Fee_Schedule.xls&wdOrigin=BROWSELINK)\n• NYS Medicaid Midwife Services Fee Schedule (https://view.officeapps.live.com/op/view. aspx?src=\nhttps%3A%2F%2Fwww.emedny.org%2FProviderManuals%2FMidwife%2FPDFS%2FMidwife_Fee_\nSchedule.xls&wdOrigin=BROWSELINK).\nUpdated fee schedules can be found within the provider manual categories listed on the eMedNY “Provider\nManual” web page, located at: https://www.emedny.org/ProviderManuals/index.aspx.\nQuestions\nAll questions should be directed to FFSMedicaidPolicy@health.ny.gov.\n***************************************************************************************************************\nJuly 2022 New York State Medicaid Update pg. 10\n\nUpdated Billing Guidance for Postpartum Maternal Depression\nScreening\nThis article supersedes the Postpartum Maternal Depression Screening: Updated Billing Guidance\narticle published in the August 2016 issue of the Medicaid Update, located at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2016/aug16_mu.pdf. Effective\nAugust 1, 2022, for New York State (NYS) Medicaid fee-for-service (FFS), and effective October 1, 2022,\nfor Medicaid Managed Care (MMC) Plans [including mainstream MMC Plans, Human Immunodeficiency Virus\n(HIV)", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0019", "char_start": 33250, "char_end": 35250, "pages": [11], "text": "gram/update/2016/aug16_mu.pdf. Effective\nAugust 1, 2022, for New York State (NYS) Medicaid fee-for-service (FFS), and effective October 1, 2022,\nfor Medicaid Managed Care (MMC) Plans [including mainstream MMC Plans, Human Immunodeficiency Virus\n(HIV) Special Needs Plans (HIV-SNPs), as well as Health and Recovery Plans (HARPs)], postpartum\nmaternal depression screening using a validated screening tool may be reimbursed up to four times within\nthe first 12 months after the end of the pregnancy. Screening can be provided by the maternal health care\nprovider and/or by the infant's health care provider. This is an increase from the previous limit of three times\nwithin the first 12 months postpartum.\nThis reimbursement is in addition to the payment for an Evaluation and Management (E&M) service when\nmaternal depression screening is provided postpartum. Maternal depression screening can be provided by\nthe maternal health care provider and/or by the infant's health care provider up to 12 months postpartum. This\nservice can be integrated into the well-child care checkup schedule. Providers of infant health care may bill\nfor postpartum maternal depression screening under the infant's Medicaid identification number (ID). The\nCurrent Procedural Terminology (CPT) codes to be used for maternal depression screening include the\nfollowing:\n• “G8431” [with the HD modifier (Pregnant/parenting)] – Screening for clinical depression is\ndocumented as being positive and a follow-up plan is documented.\n• “G8510” [with the HD modifier (Pregnant/parenting)] – Screening for clinical depression is\ndocumented as negative; a follow-up plan is not required.\nIf the mother screens positive for depression, then the mother must be further evaluated for diagnosis and\ntreatment. Medical practices that do not have the capacity to evaluate and treat mothers who screen positive\nfor depression must have a referral process in place for these beneficiaries. Mothers who currently have\ndepression, or have a his", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0020", "char_start": 35000, "char_end": 37000, "pages": [11, 12], "text": "gnosis and\ntreatment. Medical practices that do not have the capacity to evaluate and treat mothers who screen positive\nfor depression must have a referral process in place for these beneficiaries. Mothers who currently have\ndepression, or have a history of major depression, warrant particularly close monitoring and evaluation. The\ncurrent standard of care for pregnant persons requires that all pregnant persons receive depression screening\nas part of their routine antepartum care. Maternal depression screening that occurs antepartum is included in\nthe payment for the E&M service.\nA maternal health care provider is defined as a: physician, midwife (MW), nurse practitioner (NP), physician\nassistant (PA), or other health care practitioner acting within their lawful scope of practice. The infant's health\ncare provider is also defined as a: physician, NP, PA, or other health care practitioner acting within their lawful\nscope of practice. Additional information is available on the NYS DOH “Medicaid Perinatal Care Standards”\nweb page, located at: https://www.health.ny.gov/health_care/medicaid/standards/perinatal_care/.\nDepression Screening and Referral Tools\nThere are multiple depression screening tools available for use that can be completed in less than ten\nminutes. The American Academy of Pediatrics (AAP) shares the following resources and guidance on\ndepression screening tools below:\n• AAP “Perinatal Depression Screening Resources” web page (https://www.aap.org/en/patient-\ncare/screening-technical-assistance-and-resource-center/screening-resource-library/perinatal-\ndepression/?page=1&sortDirection=1&sortField=Year)\n• AAP Incorporating Recognition and Management of Perinatal Depression Into Pediatric Practice\narticle (https://publications.aap.org/pediatrics/article/143/1/e20183259/37241/Incorporating-\nRecognition-and-Management-of?autologincheck=redirected)\nJuly 2022 New York State Medicaid Update pg. 11\n\nAdditional validated screening tools for maternal depression can ", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0021", "char_start": 36750, "char_end": 38750, "pages": [11, 12], "text": "//publications.aap.org/pediatrics/article/143/1/e20183259/37241/Incorporating-\nRecognition-and-Management-of?autologincheck=redirected)\nJuly 2022 New York State Medicaid Update pg. 11\n\nAdditional validated screening tools for maternal depression can be found on the NYS Department of Health\n(DOH) “Screening for Maternal Depression” web page, located at: https://www.health.ny.gov/\ncommunity/pregnancy/health_care/perinatal/maternal_depression/providers/screening.htm. Additional\nguidance on referral information can be found on the following web pages:\n• NYS DOH “Additional Resources For Maternal Health Care Providers” web page (https://www.\nhealth.ny.gov/community/pregnancy/health_care/perinatal/maternal_depression/providers/additional\n_resources.htm)\n• NYS Office of Mental Health (OMH) “Directory of OMH Facilities” web page (https://omh.ny.gov/\nomhweb/aboutomh/omh_facility.html)\n• Postpartum Resource Center of New York “Perinatal Mood and Anxiety Disorder State-wide Resource\nDirectory” web page (https://postpartumny.org/resourcedirectory/)\nBilling Guidance\nIf maternal depression screening is provided postpartum by the maternal health care provider, the service\ncan be reimbursed in addition to the E&M visit. Providers should continue to bill for this service using CPT\ncode “G8431” in conjunction with the HD modifier for a positive depression screen of the mother and “G8510”\nin conjunction with the HD modifier when the screening returns a negative result. If maternal depression\nscreening is performed on the same day as the infant's primary care visit (E&M) by the infant's health care\nprovider, one claim can be submitted for both services using the appropriate \"G\" series code (“G8431” or\n“G8510”) with the HD modifier under the infant's Medicaid ID. Alternatively, providers may bill this service\nseparately under the mother's Medicaid ID.\nQuestions and Additional Information:\n• Medicaid FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000.\n• Me", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0022", "char_start": 38500, "char_end": 40500, "pages": [12, 13], "text": " infant's Medicaid ID. Alternatively, providers may bill this service\nseparately under the mother's Medicaid ID.\nQuestions and Additional Information:\n• Medicaid FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000.\n• Medicaid FFS coverage and policy questions should be directed to the Office of Health Insurance\nPrograms (OHIP) Division of Program Development and Management (DPDM) by telephone at\n(518) 473-2160 or by email at FFSMedicaidPolicy@health.ny.gov.\n• Medicaid FFS Pharmacy coverage and policy questions should be directed to the Medicaid\nPharmacy Policy Unit by telephone at (518) 486-3209 or by email at PPNO@health.ny.gov.\n• MMC general coverage questions should be directed to the OHIP Division of Health Plan\nContracting and Oversight (DHPCO) by email at covques@health.ny.gov or by telephone at\n(518) 473-1134.\n• MMC reimbursement, billing, and/or documentation requirement questions should be directed to\nenrollee MMC Plans.\n• MMC Plan contact information can be found in the eMedNY New York State Medicaid Program\nInformation for All Providers Managed Care Information document, located at:\nhttps://www.emedny.org/ProviderManuals/AllProviders/PDFS/Information_for_All_Providers_Ma\nnaged_Care_Information.pdf.\n• MMC plan-specific policies and billing guidance for PADs can be found on the NYS DOH “New\nYork State Medicaid Managed Care (MMC) Pharmacy Benefit Information Center” website,\nlocated at: https://mmcdruginformation.nysdoh.suny.edu.\n***************************************************************************************************************\nJuly 2022 New York State Medicaid Update pg. 12\n\nAll Providers\nUpdated Identification, Specimen Collection, Testing, Vaccine\nAdministration, and Treatment for Suspected Cases of\nOrthopoxvirus/Monkeypox\nThis article supersedes the Identification, Specimen Collection, Testing, Vaccine Administration, and\nTreatment for Suspected Cases of Orthopoxvirus/Monkeypox article published in the June 2022", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0023", "char_start": 40250, "char_end": 42250, "pages": [13], "text": "Treatment for Suspected Cases of\nOrthopoxvirus/Monkeypox\nThis article supersedes the Identification, Specimen Collection, Testing, Vaccine Administration, and\nTreatment for Suspected Cases of Orthopoxvirus/Monkeypox article published in the June 2022\nMedicaid Update, located at: https://www.health.ny.gov/health_care/medicaid/program/update\n/2022/no07_2022-06.htm. On July 29, 2022, New York State (NYS) Governor Kathy Hochul signed Executive\nOrder No. 20, located at: https://www.governor.ny.gov/sites/default/files/2022-07/EO%2020.pdf, declaring a\ndisaster emergency in NYS due to the ongoing spread of the monkeypox virus.\nThe Centers for Disease Control and Prevention (CDC) is tracking multiple cases of orthopoxvirus/monkeypox\nthat have been reported in several countries that do not normally report orthopoxvirus/monkeypox, including\nthe United States (U.S.). The CDC is urging health care providers in the U.S. to be on alert for patients who\nhave rash illnesses consistent with orthopoxvirus/monkeypox, as explained on the CDC Monkeypox “Clinical\nRecognition” web page, located at: https://www.cdc.gov/poxvirus/monkeypox/clinicians/clinical-recognition\n.html.\nAn orthopoxvirus/monkeypox rash may look like blisters or pimples, and can appear on the face, inside the\nmouth, or on other areas of the body such as the genitals, anus, hands, or feet. In addition to a rash, other\nsymptoms may include fever, chills, headache, swollen lymph nodes, exhaustion, muscle aches, and\nbackache. Additional information on the symptoms related to orthopoxvirus/monkeypox can be found on the\nCDC Monkeypox “Signs and Symptoms” web page, located at: https://www.cdc.gov/poxvirus\n/monkeypox/symptoms.html. Updated total cases of confirmed orthopoxvirus/monkeypox in NYS can be\nfound on the NYS Department of Health (DOH) “Monkeypox” web page, located at:\nhttps://health.ny.gov/diseases/communicable/zoonoses/monkeypox/#:~:text=As%20of%20July%201%2C%\n202022,and%201%20in%20Suffolk%20County.\nTesting\nMonkeypox", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0024", "char_start": 42000, "char_end": 44000, "pages": [13], "text": "eypox in NYS can be\nfound on the NYS Department of Health (DOH) “Monkeypox” web page, located at:\nhttps://health.ny.gov/diseases/communicable/zoonoses/monkeypox/#:~:text=As%20of%20July%201%2C%\n202022,and%201%20in%20Suffolk%20County.\nTesting\nMonkeypox testing is available at the NYS DOH Wadsworth Center Biodefense Laboratory and the New York\nCity (NYC) Public Health Laboratory. Specimen collection and submission must be coordinated with the Local\nCounty Health Department (LCHD) and/or NYS DOH. Within NYC, coordination must be done in consultation\nwith the NYC DOH.\nThe NYS DOH Wadsworth Center will accept specimens collected and transported in viral transport media\n(VTM) or collected and transported dry. Specimens in VTM can be tested for orthopoxvirus, varicella-zoster\nvirus (VZV), and herpes simplex viruses (HSVs): HSV-1 and HSV-2. Specimens collected dry can only be\ntested for orthopoxvirus. Testing for other viruses should be done locally. Providers can refer to the NYS\nDOH, Wadsworth Center “Monkeypox Testing Guidance” web page, located at:\nhttps://www.wadsworth.org/monkeypox-testing-guidance, for additional testing information. The NYC Public\nHealth Laboratory will accept specimens collected and transported in viral transport media (VTM) or collected\nand transported dry. Specimens will only be tested for orthopoxvirus. Testing for other viruses should be done\nlocally. Providers can refer to the Instructions for Submission of Specimens for Monkeypox Testing to the\nNew York City Public Health Laboratory, located at: https://www1.nyc.gov/assets/doh/downloads/pdf/labs/\nmonkeypox-specimen-testing.pdf, for more information.\nAdditional labs are being approved to support diagnostic orthopoxvirus testing. Effective July 26, 2022,\nenrolled NYS Medicaid lab providers approved for this testing may bill the Current Procedural Terminology\n(CPT) code “87593” [Infectious agent detection by nucleic acid (DNA or RNA); orthopoxvirus (e.g.,\nmonkeypox virus, cowpox virus, vaccinia v", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0025", "char_start": 43750, "char_end": 45750, "pages": [13, 14], "text": "022,\nenrolled NYS Medicaid lab providers approved for this testing may bill the Current Procedural Terminology\n(CPT) code “87593” [Infectious agent detection by nucleic acid (DNA or RNA); orthopoxvirus (e.g.,\nmonkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each] for testing provided to\nMedicaid fee-for-service (FFS) members. Providers who are already receiving funding from another source\nfor these tests, are not eligible for reimbursement. A temporary fee of $51.31 has been assigned, until more\ninformation is available.\nJuly 2022 New York State Medicaid Update pg. 13\n\nThe Food and Drug Administration (FDA) made a recent announcement that test results from commercial\nlaboratories showing orthopoxvirus detected are definitive for monkeypox virus, because it is the only\ncirculating orthopoxvirus in the U.S. Although no longer a requirement, the CDC would like to continue to\nreceive positive samples from commercial laboratories to aid in surveillance. Without confirmation,\ncommercial laboratories must also be clear in their report that the sample was positive for orthopoxvirus and\nassumed to definitively indicate monkeypox.\nReporting\nHealth care providers must immediately report suspected cases of orthopoxvirus/monkeypox to their LCHD.\nReporting should be to the county where the patient resides. For reporting outside of NYC, contact information\ncan be found on the NYS DOH “County Health Departments” web page, located at:\nhttps://www.health.ny.gov/contact/contact_information/. Providers who are unable to reach the LCHD where\nthe patient resides must contact the NYS DOH Bureau of Communicable Disease Control (BCDC) by\ntelephone at (518) 473-4439 during business hours or (866) 881-2809 during evenings, weekends, and\nholidays. NYC residents suspected of monkeypox infection should be reported to the NYC DOH Provider\nAccess Line (PAL) by telephone at (866) 692-3641.\nFor additional information including specimen collection and virus images, providers", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0026", "char_start": 45500, "char_end": 47500, "pages": [14], "text": ", weekends, and\nholidays. NYC residents suspected of monkeypox infection should be reported to the NYC DOH Provider\nAccess Line (PAL) by telephone at (866) 692-3641.\nFor additional information including specimen collection and virus images, providers can refer to the\nHealth Advisory: Monkeypox Outbreak, United States, released on June 17, 2022 by the Wadsworth\nCenter, NYC Public Health Laboratory, and CDC: https://health.ny.gov/diseases/communicable\n/zoonoses/monkeypox/docs/2022-06-17_han.pdf.\nVaccines\nThe CDC is providing two, free immunizations, licensed by the U.S. FDA, JYNNEOS (also known as\nImvamune or Imvanex) and ACAM2000. Monkeypox vaccine administration is a covered benefit in both NYS\nMedicaid FFS and Medicaid Managed Care (MMC). NYS Medicaid FFS and MMC Plans will reimburse\nproviders for the administration of these vaccines. For individuals enrolled in MMC, providers should check\nwith the individual’s MMC Plan for billing instructions. LCHD Article 28 clinics may bill NYS Medicaid FFS for\nthe administration of these vaccines to Medicaid FFS members by submitting an ordered ambulatory claim\nwith the following CPT codes effective for dates of service on or after July 26, 2022.\nCPT Code Description Vaccine Name\nCode\n90611 Smallpox and monkeypox vaccine, attenuated vaccinia virus, live, JYNNEOS (Imvamune or\nnonreplicating, preservative free, 0.5 mL dosage, suspension, for Imvanex)\nsubcutaneous injection\n90622 Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for ACAM2000\npercutaneous use\nFor Medicaid FFS members 19 years of age and older, providers must bill the CPT code “90471” for vaccine\nadministration and the CPT code of the vaccine administered appended with the \"FB\" modifier (indicating an\nadult vaccine supplied at no cost). Providers will be reimbursed $13.23 for the administration of the vaccine.\nFor Medicaid FFS members under 19 years of age, providers must bill the CPT code “90460” for vaccine\nadministration and the CPT code of th", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0027", "char_start": 47250, "char_end": 49250, "pages": [14, 15], "text": "\nadult vaccine supplied at no cost). Providers will be reimbursed $13.23 for the administration of the vaccine.\nFor Medicaid FFS members under 19 years of age, providers must bill the CPT code “90460” for vaccine\nadministration and the CPT code of the vaccine administered appended with the \"SL\" modifier (indicating a\nchild vaccine supplied at no cost). Providers will be reimbursed $17.85 for the administration of the vaccine.\nArticle 28 clinics that partner with LCHDs for vaccine administration should follow the billing guidelines listed\nabove. Similarly, private practitioners [i.e., physicians, nurse practitioners (NPs), and midwives (MWs)] may\nbill a professional claim for vaccine administration using the billing guidelines listed above.\nJuly 2022 New York State Medicaid Update pg. 14\n\nSchool Based Health Centers (SBHCs) would follow the ordered ambulatory billing instructions above and\nappend the “HA” modifier to both the CPT code for the vaccine administered (in addition to the appropriate\n“FB” or “SL” modifier) and CPT code for vaccine administration.\nFederally Qualified Health Centers (FQHCs), including SBHCs designated as FQHCs (SBHC/FQHC), may\nsubmit a Prospective Payment System (PPS) threshold clinic claim if the vaccine is administered as part of\nan encounter in which a significant procedure and/or medical visit accompanies the vaccination. FQHCs and\nSBHC/FQHCs that bill under the PPS rate should not submit a claim for reimbursement seeking the PPS\nthreshold clinic visit rate when the only service provided to a member is a vaccine administration. Instead,\nFQHCs should seek reimbursement for vaccine administration as an ordered ambulatory service following\nthe ordered ambulatory billing instructions above. SBHC/FQHC must append the “HA” modifier to both the\nCPT code for the vaccine administered (in addition to the appropriate “FB” or “SL” modifier) and CPT code\nfor vaccine administration when billing an ordered ambulatory claim.\nPlease note: Executive Order", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0028", "char_start": 49000, "char_end": 51000, "pages": [15], "text": "FQHC must append the “HA” modifier to both the\nCPT code for the vaccine administered (in addition to the appropriate “FB” or “SL” modifier) and CPT code\nfor vaccine administration when billing an ordered ambulatory claim.\nPlease note: Executive Order No.20 suspends consent requirements for reporting monkeypox vaccinations\nand requires providers to report monkeypox vaccine administrations with 72 hours of administration to the\nNew York State Immunization Information System (NYSIIS) or Citywide Immunization Registry (CIR).\nAdditional Information on NYSIIS is located on the NYS DOH “New York State Immunization Information\nSystem (NYSIIS)” web page, at: https://www.health.ny.gov/prevention/immunization/information_system/.\nAdditional information on CIR is located on the City of NY “Citywide Immunization Registry (CIR)” web page,\nat: https://www1.nyc.gov/site/doh/providers/reporting-and-services/citywide-immunization-registry-cir.page.\nPharmacy Billing\nA pharmacist may administer vaccinations against monkeypox pursuant to a patient specific or non-patient\nspecific order. Pharmacies must submit the vaccine claim via the National Council for Prescription Drug\nProgram (NCPDP) D.0 format as described below.\n• Submit the CPT code of the vaccine in field 407-D7 [Product/Service Identification Number (ID)] with\na value of $0.00 in field 409-D9 (Ingredient Cost Submitted).\n• Medicaid members 19 years of age and older:\nSubmit the CPT code “90471” for vaccine administration in field 407-D7 (Product/Service ID).\n• Medicaid members under 19 years of age:\nSubmit the CPT code “90460” for vaccine administration in field 407-D7 (Product/Service ID).\nBilling Instructions\nNCPDP D.0 Claim Segment Field Value\n436-E1 (Product/Service ID Qualifier) Value of \"09\" (HCPCS), which qualifies the code submitted in\nfield 407-D7 (Product/Service ID) as a procedure code\n407-D7 (Product/Service ID) Enter the applicable procedure codes listed above\n409-D9 (Ingredient Cost Submitted) Enter a value of $0.", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0029", "char_start": 50750, "char_end": 52750, "pages": [15, 16], "text": ") Value of \"09\" (HCPCS), which qualifies the code submitted in\nfield 407-D7 (Product/Service ID) as a procedure code\n407-D7 (Product/Service ID) Enter the applicable procedure codes listed above\n409-D9 (Ingredient Cost Submitted) Enter a value of $0.00\n442-E7 (Quantity Dispensed) Enter the value of “1” for the procedure administration code\n405-D5 (Day Supply) Enter the value of “1”\n411-DB (Prescriber ID) Enter prescriber National Provider Identifier (NPI) number\nFor guidance on origin code and serial number values that must be submitted on the claim, providers can\nrefer to the Matching Origin Codes to Correct Prescription Serial Number in Medicaid Fee-for-Service article\npublished in the July 2020 issue of the Medicaid Update, located at:\nhttps://www.health.ny.gov/health_care/medicaid/program/update/2020/docs/mu_no12_jul20.pdf.\nJuly 2022 New York State Medicaid Update pg. 15\n\nPlease note: Executive Order No.20 suspends consent requirements for reporting monkeypox vaccinations\nand requires providers to report monkeypox vaccine administrations with 72 hours of administration to the\nNew York State Immunization Information System (NYSIIS) or Citywide Immunization Registry (CIR).\nAdditional Information on NYSIIS is located on the NYS DOH “New York State Immunization Information\nSystem (NYSIIS)” web page, at: https://www.health.ny.gov/prevention/immunization/information_system/.\nAdditional information on CIR is located on the City of NY “Citywide Immunization Registry (CIR)” web page,\nat: https://www1.nyc.gov/site/doh/providers/reporting-and-services/citywide-immunization-registry-cir.page.\nTreatment\nTecovirimat, also known as TPOXX or ST-246, is FDA-approved for the treatment of human smallpox\ndisease caused by Variola virus in adults and children. Tecovirimat is used for other orthopoxvirus infections,\nincluding monkeypox, and is not FDA-approved; therefore, the CDC holds non-research expanded access\nInvestigational New Drug (EA-IND) protocol that allows for the use of ", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0030", "char_start": 52500, "char_end": 54500, "pages": [16], "text": "in adults and children. Tecovirimat is used for other orthopoxvirus infections,\nincluding monkeypox, and is not FDA-approved; therefore, the CDC holds non-research expanded access\nInvestigational New Drug (EA-IND) protocol that allows for the use of tecovirimat for primary or early empiric\ntreatment of non-variola orthopoxvirus infections, including monkeypox, in adults and children of all ages.\nTPOXX is available through the Strategic National Stockpile (SNS). To request TPOXX, clinicians and care\nfacility pharmacists can contact their state/territorial health department or CDC by calling the Emergency\nOperations Center at (770) 488-7100 or by emailing Poxvirus@cdc.gov. Additional CDC information for\nproviders regarding obtaining TPOXX can be found on the CDC Monkeypox “Information for Healthcare\nProviders on Obtaining and Using TPOXX (Tecovirimat) for Treatment of Monkeypox” web page, located at:\nhttps://www.cdc.gov/poxvirus/monkeypox/clinicians/obtaining-tecovirimat.html.\nQuestions and Additional Information:\n• Additional Information regarding orthopoxvirus/monkeypox and monkeypox vaccinations is available\non the NYS DOH “Monkeypox” web page, located at: https://health.ny.gov/diseases/\ncommunicable/zoonoses/monkeypox/, and on the NYC Health “Monkeypox (Orthopoxvirus)” web\npage, located at: https://www1.nyc.gov/site/doh/health/health-topics/monkeypox.page.\n• FFS claim questions should be directed to the eMedNY Call Center at (800) 343-9000.\n• FFS coverage and policy questions should be directed to the Office of Health Insurance Programs\n(OHIP) Division of Program Development and Management (DPDM) by telephone at (518) 473-2160\nor by email at FFSMedicaidPolicy@health.ny.gov.\n• MMC general coverage questions should be directed to the OHIP Division of Health Plan Contracting\nand Oversight (DHPCO) by email at covques@health.ny.gov or by telephone at (518) 473-1134.\n• MMC reimbursement, billing, and/or documentation requirement questions should be directed to the\nenrol", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0031", "char_start": 54250, "char_end": 56250, "pages": [16, 17], "text": "rected to the OHIP Division of Health Plan Contracting\nand Oversight (DHPCO) by email at covques@health.ny.gov or by telephone at (518) 473-1134.\n• MMC reimbursement, billing, and/or documentation requirement questions should be directed to the\nenrollee’s MMC Plan.\n• MMC Plan contact information can be found in the eMedNY New York State Medicaid Program\nInformation for All Providers – Managed Care Information document, located at:\nhttps://www.emedny.org/ProviderManuals/AllProviders/PDFS/Information_for_All_Providers_Manag\ned_Care_Information.pdf.\n***************************************************************************************************************\nJuly 2022 New York State Medicaid Update pg. 16\n\nNew York State Department of Health Launches Health Care Worker\nBonus Program\nIn July 2022, the New York State (NYS) Department of Health (DOH) launched the Health Care and Mental\nHygiene Worker Bonus (HWB) program, an incentive program for the purpose of recruiting, retaining, and\nrewarding health care and mental hygiene workers who participate in the NYS Medicaid program and meet\nspecified eligibility requirements.\nThe new HWB provision is authorized under Part ZZ of the NYS Enacted Budget for State Fiscal Year (SFY)\n2022-23 Education, Labor, Family Assistance Health and Mental Hygiene Bill, which allocated $1.2 billion for\nthe payment of retention bonuses to certain health care and mental hygiene workers, with the goal of\nincreasing the NYS health care workforce by 20 percent over the next five years. Bonuses will be awarded to\nworkers in the NYS Medicaid program who make less than $125,000 annually and remain in their positions\nfor one year. Disbursements will be commensurate with the number of hours worked during designated\nvesting periods for up to a total of $3,000 per employee.\nEmployers eligible for the HWB program funding include providers participating in Medicaid with at least\none employee, and other providers, facilities, pharmacies, and school-based he", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0032", "char_start": 56000, "char_end": 58000, "pages": [17], "text": "signated\nvesting periods for up to a total of $3,000 per employee.\nEmployers eligible for the HWB program funding include providers participating in Medicaid with at least\none employee, and other providers, facilities, pharmacies, and school-based health centers licensed under\nNYS Public Health Law, Mental Hygiene Law or Education Law, as well as certain programs funded by the\nOffice of Mental Health (OMH), Office for the Aging (OFA), Office of Addiction Services and Supports\n(OASAS), and the Office for People with Developmental Disabilities (OPWDD). Employees eligible for HWB\npayments provide hands-on health care services and can include certain front line health care, home care\nand mental hygiene practitioners, technicians, assistants, and aides. Eligible employees must currently\nreceive an annualized base salary (excluding any bonuses or overtime pay) of $125,000 or less, and can be\nfull-time, part-time, temporary, or an independent contractor.\nBonuses for employees will be determined by specific “vesting periods,” or hours worked during a consecutive\nsix-month period between October 1, 2021, through March 31, 2024. Qualified employees who work:\n• at least 20 hours but no more than 30 hours per week are eligible for a bonus of $500.\n• at least 30 hours but no more than 35 hours per week are eligible for a bonus of $1,000.\n• at least 35 hours per week are eligible for a bonus of $1,500.\nA qualified employee is entitled to a maximum of $3,000 in total bonus payments over two vesting periods.\nEmployees may not receive bonuses if they have ever been suspended or excluded from the NYS Medicaid\nprogram. Employees must be enrolled in the HWB program by their employer. Providers who are not enrolled\nin NYS Medicaid, or provide both non-NYS Medicaid and Medicaid services, will need to verify their Statewide\nFinancial System (SFS) ID. Once providers confirm that they are actively enrolled in NYS Medicaid or provide\ntheir active SFS ID, they can prepare information for subm", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0033", "char_start": 57750, "char_end": 59750, "pages": [17, 18], "text": "e both non-NYS Medicaid and Medicaid services, will need to verify their Statewide\nFinancial System (SFS) ID. Once providers confirm that they are actively enrolled in NYS Medicaid or provide\ntheir active SFS ID, they can prepare information for submission of reimbursement for eligible employees.\nEmployers must submit claims for bonus payments within 30-days after the NYS DOH publishes a vesting\nschedule for completed vesting periods, and thereafter, within 30-days after the end of each additional vesting\nperiod. Employers are required to pay bonuses within 30-days of receipt of payment on a claim for each\nqualified employee. Eligible employers can submit employees who qualify for HWB payments by creating an\naccount on the HWB online portal, located at: http://www.nysworkerbonus.com/.\nJuly 2022 New York State Medicaid Update pg. 17\n\nAdditionally, employers must be currently enrolled and maintain an active Medicaid Management Information\nSystems (MMIS) ID with eMedNY. Eligible employers without an MMIS ID can enroll on the eMedNY website,\nlocated at: www.emedny.org. The Office of the Medicaid Inspector General (OMIG) will audit eMedNY\npayments to ensure funds were appropriately claimed and dispersed by the employer. Claims determined to\nhave been inappropriately paid may be subject to recovery and may also, depending on the facts and\ncircumstances, result in the imposition of penalties and sanctions [see, SSL Section 367-w (5)(a)]. An eligible\nemployer who fails to identify, claim, and pay any bonus for more than 10 percent of workers eligible for HWB\npayments may be subject to additional penalties [see SSL Section 367-w(5)(b)].\nAdditional Information\nFor more information on the HWB program and HWB online portal, located at:\nhttp://www.nysworkerbonus.com/, providers should contact the HWB Call Center at (866) 682-0077.\n***************************************************************************************************************\nMedicaid Consumer Fact Sheets Now Avai", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0034", "char_start": 59500, "char_end": 61500, "pages": [18, 19], "text": "at:\nhttp://www.nysworkerbonus.com/, providers should contact the HWB Call Center at (866) 682-0077.\n***************************************************************************************************************\nMedicaid Consumer Fact Sheets Now Available\nMedicaid consumer fact sheets, focused on prevention, treatment, and management of health conditions, as\nwell as relevant Medicaid benefits that can be used to help members stay healthy, are available on the New\nYork State (NYS) Department of Health (DOH) \"MRT II Policies and Guidance\" web page, located at:\nhttps://www.health.ny.gov/health_care/medicaid/redesign/mrt2/policy/index.htm. Topics include asthma\ncontrol, chronic kidney disease, Coronavirus Disease 2019 (COVID-19), diabetes, high blood pressure, HIV-\nPrEP (Human Immunodeficiency Virus - Pre-Exposure Prophylaxis), periodontal disease, sickle cell disease,\nsmoking cessation, and tooth decay. Fact sheets are available in Arabic, Bengali, Chinese, English, Haitian-\nCreole, Italian, Korean, Polish, Russian, Spanish, Urdu, and Yiddish. The most recently added fact sheet\nprovides information on COVID-19 vaccination, testing, and treatment. Fact sheets are available in Arabic,\nBengali, Chinese, English, Haitian-Creole, Italian, Korean, Polish, Russian, Spanish, Urdu, and Yiddish.\n***************************************************************************************************************\nJuly 2022 New York State Medicaid Update pg. 18\n\nProvider Directory\nOffice of the Medicaid Inspector General:\nFor suspected fraud, waste, or abuse complaints/allegations, please call 1-877-87FRAUD, (877) 873-7283,\nor visit the Office of Medicaid Inspector General (OMIG) web site at: www.omig.ny.gov.\nProvider Manuals/Companion Guides, Enrollment Information/Forms/Training Schedules:\nPlease visit the eMedNY website at: www.emedny.org.\nProviders wishing to listen to the current week’s check/EFT amounts:\nPlease call (866) 307-5549 (available Thursday PM for one week for the current", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0035", "char_start": 61250, "char_end": 62794, "pages": [19], "text": ", Enrollment Information/Forms/Training Schedules:\nPlease visit the eMedNY website at: www.emedny.org.\nProviders wishing to listen to the current week’s check/EFT amounts:\nPlease call (866) 307-5549 (available Thursday PM for one week for the current week's amount).\nFor questions about billing and performing MEVS transactions:\nPlease call the eMedNY Call Center at (800) 343-9000.\nProvider Training:\nPlease enroll online for a provider seminar at: https://www.emedny.org/training/index.aspx. For individual\ntraining requests, please call (800) 343-9000.\nBeneficiary Eligibility:\nPlease call the Touchtone Telephone Verification System at (800) 997-1111.\nMedicaid Prescriber Education Program:\nFor current information on best practices in pharmacotherapy, please visit the following web sites:\n• DOH Prescriber Education Program page:\nhttps://www.health.ny.gov/health_care/medicaid/program/prescriber_education/presc-educationprog.\n• Prescriber Education Program in partnership with SUNY: http://nypep.nysdoh.suny.edu/.\neMedNY\nFor a number of services, including: change of address, updating an enrollment file due to an ownership\nchange, enrolling another NPI, or revalidating an existing enrollment, please visit the eMedNY Provider\nEnrollment page at: https://www.emedny.org/info/ProviderEnrollment/index.aspx, and choose the\nappropriate link based on provider type.\nComments and Suggestions Regarding This Publication\nPlease contact the editor, Angela Lince, at medicaidupdate@health.ny.gov.\nJuly 2022 New York State Medicaid Update pg. 19", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0036", "char_start": 62544, "char_end": 62794, "pages": [19], "text": "rollment/index.aspx, and choose the\nappropriate link based on provider type.\nComments and Suggestions Regarding This Publication\nPlease contact the editor, Angela Lince, at medicaidupdate@health.ny.gov.\nJuly 2022 New York State Medicaid Update pg. 19", "chunk_type": "text"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0037::table", "char_start": null, "char_end": null, "pages": [4], "text": "\"NYS Medicaid FFS policy for drugs administered by subcutaneous, intramuscular, or intravenous methods in\",,\r\n\"the practitioner’s office are covered for Food and Drug Administration (FDA) approved indications, or where\",,\r\nthe medically accepted indication is supported in any of the compendia described in Social Security Act,,\r\n§,1927(g)(1)(B)(i) for a medically necessary NYS Medicaid-covered service. In the absence of such a,\r\n\"recognized indication, an approved Institutional Review Board (IRB) protocol would be required with\",,\r\ndocumentation maintained in the patient's clinical file. Drugs are not covered for investigational or,,\r\nexperimental use.,,\r\n,,\r\n", "chunk_type": "table"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0038::table", "char_start": null, "char_end": null, "pages": [4], "text": "Clinical Criteria Worksheets are available for some drugs/drug classes subject to clinical criteria. These\r\nworksheets are designed to ensure claim documentation and outline completion as well as provide step-by-\r\n\"step clinical and claim documentation requirements for drugs. Legible, completed worksheets can be\"\r\nsubmitted in lieu of detailed medical documentation.\r\n", "chunk_type": "table"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0039::table", "char_start": null, "char_end": null, "pages": [6], "text": "NYS Medicaid FFS covers medically necessary vaccines as recommended by the Centers for Disease\r\nControl and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP). Additional information\r\non ACIP vaccine recommendations and guidelines can be found on the CDC “ACIP Vaccine\r\n\"Recommendations and Guidelines” web page, located at: https://www.cdc.gov/vaccines/hcp/acip-\"\r\nrecs/index.html.\r\n", "chunk_type": "table"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0040::table", "char_start": null, "char_end": null, "pages": [6], "text": "\"Providers should not bill multiple claim lines with the same J-code drugs on the same date of service, even if\"\r\nthe drugs administered have different NDCs. Providers should combine all units of the J-code drug\r\nadministered and bill it on one claim line reporting the NDC that has the highest number of units administered.\r\n\"If the same number of units were administered for each NDC/J-code, providers should choose one NDC to\"\r\nuse for the submitted claim.\r\n", "chunk_type": "table"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0041::table", "char_start": null, "char_end": null, "pages": [7], "text": "\"Certain drugs [e.g., Chemotherapy (APG 430-434, 441, and 443), Class XIII and XIV Combined\"\r\n\"Chemotherapy and Pharmacotherapy Drugs (APG 465 and 466), Minor Chemotherapy Drugs (APG 495),\"\r\nand Class IV Therapeutic Radiopharmaceuticals (APG 246)] are carved out of the APG reimbursement\r\nmethodology. Providers should seek reimbursement for these services via the eMedNY Ordered Ambulatory\r\n\"Fee Schedule, located at: https://www.emedny.org/ProviderManuals/OrderedAmbulatory/. The “Never Pay”\"\r\n\"APGs and procedures lists are available on the NYS DOH “Never Pay Lists” web page, located at:\"\r\nhttps://www.health.ny.gov/health_care/medicaid/rates/methodology/apg_carve_out.htm.\r\n\"\"\r\n", "chunk_type": "table"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0042::table", "char_start": null, "char_end": null, "pages": [14], "text": "\"For additional information including specimen collection and virus images, providers can refer to the\",,,,,,\r\n\"Health Advisory: Monkeypox Outbreak, United States, released on June 17, 2022 by the Wadsworth\",,,,,,\r\n\"Center, NYC Public Health Laboratory, and CDC: https://health.ny.gov/diseases/communicable\",,,,,,\r\n/zoonoses/monkeypox/docs/2022-06-17_han.pdf.,,,,,,\r\n,,,,,,\r\nVaccines,,,,,,\r\n\"The CDC is providing two, free immunizations, licensed by the U.S. FDA,\",,,,,JYNNEOS (also known as,\r\nImvamune or Imvanex) and ACAM2000,,,,. Monkeypox vaccine administration is a covered benefit in both NYS,,\r\nMedicaid FFS and Medicaid Managed Care (MMC). NYS Medicaid FFS and MMC Plans will reimburse,,,,,,\r\n\"providers for the administration of these vaccines. For individuals enrolled in MMC, providers should check\",,,,,,\r\nwith the individual’s MMC Plan for billing instructions. LCHD Article 28 clinics may bill NYS Medicaid FFS for,,,,,,\r\nthe administration of these vaccines to Medicaid FFS members by submitting an ordered ambulatory claim,,,,,,\r\n\"with the following CPT codes effective for dates of service on or after July 26, 2022.\",,,,,,\r\n,,,,,,\r\n,CPT,,Code Description,,,Vaccine Name\r\n,Code,,,,,\r\n90611,,,\"Smallpox and monkeypox vaccine, attenuated vaccinia virus, live,\nnonreplicating, preservative free, 0.5 mL dosage, suspension, for\nsubcutaneous injection\",,,\"JYNNEOS (Imvamune or\nImvanex)\"\r\n90622,,,\"Vaccinia (smallpox) virus vaccine, live, lyophilized, 0.3 mL dosage, for\npercutaneous use\",,,ACAM2000\r\n", "chunk_type": "table"}
{"doc_id": "mu_no8_jul22_pr.pdf", "chunk_id": "mu_no8_jul22_pr.pdf::0043::table", "char_start": null, "char_end": null, "pages": [15], "text": ",NCPDP D.0 Claim Segment Field,,,,Value,\r\n436-E1 (Product/Service ID Qualifier),436-E1 (Product/Service ID Qualifier),,,\"Value of \"\"09\"\" (HCPCS), which qualifies the code submitted in\nfield 407-D7 (Product/Service ID) as a procedure code\",,\r\n407-D7 (Product/Service ID),,,,Enter the applicable procedure codes listed above,,\r\n409-D9 (Ingredient Cost Submitted),,,,Enter a value of $0.00,,\r\n442-E7 (Quantity Dispensed),,,,Enter the value of “1” for the procedure administration code,,\r\n405-D5 (Day Supply),,,,Enter the value of “1”,,\r\n,411-DB (Prescriber ID),,,Enter prescriber National Provider Identifier (NPI) number,,\r\n", "chunk_type": "table"}
